1. D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer’s disease
- Author
-
Hou, Ke, Pan, Hope, Shahpasand-Kroner, Hedieh, Hu, Carolyn, Abskharon, Romany, Seidler, Paul, Mekkittikul, Marisa, Balbirnie, Melinda, Lantz, Carter, Sawaya, Michael R, Dolinsky, Joshua L, Jones, Mychica, Zuo, Xiaohong, Loo, Joseph A, Frautschy, Sally, Cole, Greg, and Eisenberg, David S
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Neurological ,Brain ,Animals ,Mice ,Transgenic ,Humans ,Mice ,Alzheimer Disease ,Disease Models ,Animal ,Amyloid ,Peptides ,tau Proteins ,Behavior ,Animal ,Magnetite Nanoparticles ,Protein Aggregation ,Pathological - Abstract
Amyloid fibrils of tau are increasingly accepted as a cause of neuronal death and brain atrophy in Alzheimer's disease (AD). Diminishing tau aggregation is a promising strategy in the search for efficacious AD therapeutics. Previously, our laboratory designed a six-residue, nonnatural amino acid inhibitor D-TLKIVW peptide (6-DP), which can prevent tau aggregation in vitro. However, it cannot block cell-to-cell transmission of tau aggregation. Here, we find D-TLKIVWC (7-DP), a d-cysteine extension of 6-DP, not only prevents tau aggregation but also fragments tau fibrils extracted from AD brains to neutralize their seeding ability and protect neuronal cells from tau-induced toxicity. To facilitate the transport of 7-DP across the blood-brain barrier, we conjugated it to magnetic nanoparticles (MNPs). The MNPs-DP complex retains the inhibition and fragmentation properties of 7-DP alone. Ten weeks of MNPs-DP treatment appear to reverse neurological deficits in the PS19 mouse model of AD. This work offers a direction for development of therapies to target tau fibrils.
- Published
- 2024